Get the Stockscreener App
1.45
0.00%
0.00
Pre-market:
1.40
-0.05
-3.45%
Actinium Pharmaceuticals Inc stock is traded at $1.45, with a volume of 81,217.
It is up +0.00% in the last 24 hours and up +7.41% over the past month.
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options. Its lead product candidate is Iomab-B that is in Phase III clinical studies for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older. The company is also developing Actimab-A, which is in Phase II clinical trials for the treatment of patients newly diagnosed with AML over the age of 60, as well as in Phase I clinical trials in combination with CLAG-M for patients with relapsed or refractory AML; and Actimab-M that is in Phase I clinical trials for patients with refractory multiple myeloma. Actinium Pharmaceutical, Inc. was founded in 2000 and is based in New York, New York.
See More
Previous Close:
$1.45
Open:
$1.45
24h Volume:
81,217
Relative Volume:
0.40
Market Cap:
$45.23M
Revenue:
$81,000
Net Income/Loss:
$-41.04M
P/E Ratio:
-1.1011
EPS:
-1.3169
Net Cash Flow:
$-30.69M
1W Performance:
+0.00%
1M Performance:
+7.41%
6M Performance:
-15.20%
1Y Performance:
+19.83%
1-Day Range:
$1.41
$1.54
1-Week Range:
$1.33
$1.54
52-Week Range:
$1.06
$2.41
Actinium Pharmaceuticals Inc Stock (ATNM) Company Profile
Name
Actinium Pharmaceuticals Inc
Sector
Industry
Phone
646-767-3870
Address
275 Madison Avenue, 7th Floor, New York, NY
Compare ATNM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATNM
Actinium Pharmaceuticals Inc
|
1.45 | 45.23M | 81,000 | -41.04M | -30.69M | -1.3169 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Actinium Pharmaceuticals Inc Stock (ATNM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-07-24 | Downgrade | B. Riley Securities | Buy → Neutral |
| May-14-24 | Initiated | Stephens | Overweight |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Feb-21-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Sep-08-22 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-25-22 | Initiated | B. Riley Securities | Buy |
| Nov-05-20 | Initiated | Alliance Global Partners | Buy |
| Dec-06-17 | Initiated | B. Riley FBR, Inc. | Buy |
| Oct-23-17 | Resumed | ROTH Capital | Buy |
| Sep-14-17 | Initiated | Maxim Group | Buy |
| Aug-25-16 | Initiated | ROTH Capital | Buy |
| Feb-29-16 | Initiated | H.C. Wainwright | Buy |
| Oct-15-15 | Initiated | FBR Capital | Outperform |
| Oct-01-14 | Initiated | MLV & Co | Buy |
| Jul-22-14 | Initiated | Canaccord Genuity | Buy |
View All
Actinium Pharmaceuticals Inc Stock (ATNM) Latest News
Why analysts recommend Actinium Pharmaceuticals Inc. (Delaware) stock2025 Earnings Surprises & Daily Entry Point Trade Alerts - Newser
How Actinium Pharmaceuticals Inc. (Delaware) stock expands through international markets2025 Short Interest & Real-Time Chart Pattern Alerts - Newser
Will Actinium Pharmaceuticals Inc. (Delaware) stock beat Nasdaq index returnsChart Signals & Consistent Profit Alerts - Newser
Can Actinium Pharmaceuticals Inc. (7AY1) stock double in coming yearsWeekly Stock Report & Short-Term High Return Ideas - Newser
Why hedge funds are buying Actinium Pharmaceuticals Inc. stockMarket Activity Report & Real-Time Volume Spike Alerts - Newser
Is Actinium Pharmaceuticals Inc. (7AY1) stock a momentum leaderJuly 2025 Volume & Fast Gain Swing Trade Alerts - Newser
Why Actinium Pharmaceuticals Inc. stock is a value investor pick2025 Market WrapUp & Expert Approved Trade Ideas - Newser
Jeri Kim: Thrilled to Join Actinium Pharmaceuticals as VP, Head of Solid Tumor Clinical Development - Oncodaily
Will Actinium Pharmaceuticals Inc. (Delaware) stock gain from lower interest ratesWeekly Trend Report & Weekly Top Gainers Alerts - Newser
Will Actinium Pharmaceuticals Inc. stock benefit from green energy trendsJobs Report & Daily Entry Point Alerts - Newser
Why retail traders accumulate Actinium Pharmaceuticals Inc. (Delaware) stockJuly 2025 Review & Real-Time Chart Breakout Alerts - Newser
How Actinium Pharmaceuticals Inc. (7AY1) stock valuation compares with sectorQuarterly Portfolio Summary & Weekly High Potential Alerts - Newser
How cyclical is Actinium Pharmaceuticals Inc. (7AY1) stock compared to rivalsJuly 2025 Volume & Smart Investment Allocation Insights - Newser
Actinium’s ATNM-400 shows efficacy in resistant breast cancers By Investing.com - Investing.com Nigeria
Actinium Pharmaceuticals (ATNM) Unveils Promising Preclinical Da - GuruFocus
Actinium's ATNM-400 shows strong efficacy in TNBC, beats therapy resistance at SABCS - marketscreener.com
Actinium’s ATNM-400 shows efficacy in resistant breast cancers - Investing.com
Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposiu - PR Newswire
Securities Fraud Class Action Filed Against Actinium Pharmaceutic - The National Law Review
Decliners Report: Will Actinium Pharmaceuticals Inc. stock outperform value stocksCPI Data & Safe Swing Trade Setup Alerts - BỘ NỘI VỤ
Will Actinium Pharmaceuticals Inc. stock outperform Dow Jones index2025 Market Overview & Precise Entry and Exit Recommendations - BỘ NỘI VỤ
Bull Bear: Can Actinium Pharmaceuticals Inc. stock continue upward trend2025 Retail Activity & AI Enhanced Trading Alerts - moha.gov.vn
Actinium Pharmaceuticals elects directors and approves proposals at annual meeting - Investing.com Nigeria
Actinium Pharmaceuticals elects directors and approves proposals at annual meeting By Investing.com - Investing.com South Africa
Actinium Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks
Actinium ATNM holders back board, 3-year say-on-pay cycle - Stock Titan
Why institutional investors increase stakes in Actinium Pharmaceuticals Inc. (7AY1) stock - newser.com
Is Actinium Pharmaceuticals Inc. (Delaware) stock a fit for income portfoliosJuly 2025 Catalysts & Advanced Technical Signal Analysis - newser.com
How Actinium Pharmaceuticals Inc. stock benefits from global expansionMarket Trend Report & Reliable Entry Point Alerts - newser.com
HC Wainwright Has Bullish Outlook for ATNM FY2025 Earnings - Defense World
How Actinium Pharmaceuticals Inc. (Delaware) stock responds to bond marketDollar Strength & AI Powered Market Entry Ideas - newser.com
What is the fair value estimate for Actinium Pharmaceuticals Inc. (7AY1) stock in 20252025 Winners & Losers & Verified Technical Signals - newser.com
Is Actinium Pharmaceuticals Inc. (7AY1) stock attractive for dividend growthJuly 2025 Volume & Fast Exit and Entry Strategy Plans - newser.com
Will Actinium Pharmaceuticals Inc. (Delaware) stock extend growth storyGDP Growth & Stepwise Trade Execution Plans - newser.com
Actinium Pharmaceuticals Inc Stock (ATNM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):